Glancy Prongay Wolke says Aardvark investors may seek lead plaintiff role
Glancy Prongay Wolke & Rotter LLP says investors with losses in Aardvark Therapeutics securities may seek to lead a securities fraud class action tied to claims about ARD-101.
Glancy Prongay Wolke & Rotter LLP said Aug. 31, 2026, that investors who say they lost money in Aardvark Therapeutics, Inc. securities may seek to serve as lead plaintiff in a securities fraud class action. The firm said the complaint covers purchases or other transactions between Feb. 10, 2025, and May 14, 2026, and sets an Oct. 13, 2026, lead-plaintiff deadline.
The release says no class has been certified yet. It also says investors may retain counsel of their choice or take no action and remain absent class members.
According to the press release, the complaint alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about Aardvark Therapeutics’ business, operations and prospects. The release says the allegations center on ARD-101, including claims that the drug was less safe than investors were led to believe and that its clinical, regulatory and commercial prospects were overstated.
The release identifies Aardvark Therapeutics as the company at issue and says the claims are part of a securities fraud class action. It does not say that any court has ruled on the allegations. The notice is an attorney-advertising press release from the firm, which says it is a leading national shareholder rights law firm.
The filing deadline listed in the release is Oct. 13, 2026. The firm’s notice also says it provides contact options for investors who want to ask about the case.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.